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Ole Andreas Andreassen1 and Petter Andreas Ringen3Abstract
Background: There is limited knowledge about how environmental factors affect the course of bipolar disorder
(BD). Cannabis has been proposed as a potential risk factor for poorer course of illness, but the role of cannabis use
has not been studied in a first treatment BD I sample.
Methods: The present study examines the associations between course of illness in first treatment BD I and
continued cannabis use, from baseline to one year follow up. Patients (N = 62) with first treatment DSM-IV BD I were
included as part of the Thematically Organized Psychosis study (TOP), and completed interviews and self-report
questionnaires at both baseline and follow up. Cannabis use within the last six months at baseline and use between
baseline and follow up (“continued use”) was recorded.
Results: After controlling for confounders, continued cannabis use was significantly associated with elevated mood
(YMRS) and inferior global functioning (GAF-F) at follow up. Elevated mood mediated the effect of cannabis use on
global functioning.
Conclusions: These results suggest that cannabis use has clinical implications for the early course of BD by increasing
mood level. More focus on reducing cannabis use in clinical settings seems to be useful for improving outcome in
early phase of the disorder.
Keywords: Cannabis, BipolarBackground
The prevalence of substance use in bipolar disorder
(BD) is high [1-3] with cannabis being the most com-
monly used drug [3]. This is of interest since cannabis
has been indicated as a risk factor for developing BD
[4-6]. Cannabis use has also been associated with sever-
ity indicators in chronic BD, including earlier age of on-
set for the first affective episode [7-13], increased risk of
manic episodes [4,14], prolonged duration of episodes
[4-6], switch to mania in depressed individuals [15] and
increased suicidal ideation and suicide risk [16,17], in
addition to a more severe general course of the illness* Correspondence: l.r.kvitland@medisin.uio.no
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unless otherwise stated.[18-20]. Cannabis abuse has furthermore been shown to
predict poorer medication adherence in BD patients
[21]. Most of these studies have included patients mainly
in the chronic phase of illness after multiple mood epi-
sodes, and we cannot rule out the possibility that these
findings are biased by a selection of patients with a
more severe course, possibly being more prone to self-
medication with cannabis.
Longitudinal studies of BD samples recruited at first
treatment are very few. Two follow-up studies of first
time hospitalized patients with BD I indicate that patients
with cannabis use spend more time in affective episodes
and exhibit more rapid cycling over the first year of treat-
ment [22], and that periods with cannabis use coincide
with periods with manic and hypomanic episodes over a
mean follow-up period of 4.5 years [6]. Both studies sug-
gest that continued cannabis use in patients with recentlyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ness. Since these two studies are based on hospitalized pa-
tients in two university hospitals with well-acknowledged
BD research groups, their patient samples might be biased
towards patients with a higher severity of illness.
The current study is based on patients recruited dur-
ing their first adequate treatment for a manic episode
from both inpatient and outpatient services in a catch-
ment area based treatment system, and subsequently
followed up after one year. We here aim to ascertain the
rate of continued cannabis use over the first year of
treatment in patients with recent onset BD and identify
clinical outcomes associated with continued use, by ex-
ploring the relationship between cannabis use patterns
over the follow-up period and clinical status at one year
follow-up.
Methods
One hundred and one patients with recent onset DSM-
IV [23] BD-I were recruited consecutively from 2003
until 2013 from in- and outpatient units at all major
hospitals in the Oslo area as a part of The Thematically
Organized Psychosis (TOP) Study at the University of
Oslo and Oslo University Hospital. The patients had
both psychotic and non-psychotic forms of bipolar dis-
order. Out of these, 62 patients (63%) participated in a
personal follow-up examination after one year. Of the 39
patients that did not attend the follow-up, 20 had de-
cided to withdraw from the study, 18 had moved and
were impossible to reach and one patient had died.
There were no significant differences in baseline demo-
graphic and clinical characteristics between follow-up
participants and study drop-outs.
The full inclusion criteria were as follows: meeting
DSM-IV diagnostic criteria for BD I, being within the
first year of receiving adequate treatment for a manic
episode, age between 17 – 65 years. Patients were ex-
cluded from the study if they had pronounced cognitive
deficits (IQ lower than 70), a neurological disorder, mod-
erate/severe head injury, or were not able to speak a
Scandinavian language or to give written informed con-
sent. The patients were given both oral and written de-
scriptions of the study before consenting to participate.
The study was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate.
Assessments
Patients referred to the study were interviewed by
trained research fellows (psychologists and medical doc-
tors). Diagnosis and episodes of illness were determined
at baseline using the Structural Clinical Interview for
DSM-IV Axis I disorders (SCID module I, chapters A-E)
[24], with the aid of medical charts. For more details, see[1]. Patients were interviewed in detail, based on a com-
mon semi-structural interview form, about substance
use in the six months prior to inclusion and in the
follow-up period. Forty-seven patients did not use can-
nabis at any point during this period, 7 patients used
cannabis at baseline but not at follow-up, 2 patients
started to use cannabis in the follow-up period while 6
patients used cannabis at both time points. Based on
these data, the sample was divided into those with con-
tinued cannabis use (defined as any cannabis use at both
time points, n = 6) and those without continued use (the
rest of the patient group, i.e. both non-users and those
using at one but not both time-points, n = 56). The con-
tinued use patients reported an average use of cannabis
at both baseline and follow up of 2–3 times a week.
Global functioning was measured using the function-
ing part of the Global Assessment Functioning scale split
version (GAF-F) [25,26]. Cut-off for functional recovery
was set at a GAF score of 61 [27]. Current depressive
symptoms were assessed with the Inventory of Depres-
sive Symptoms – Clinician rated (IDS-C) [28], current
manic symptoms were rated with the Young Mania Rating
Scale [29], and current psychotic symptoms were assessed
with the positive symptoms subscale of the Positive
And Negative Syndrome Scale (PANSS) [30] at both
time points.
Medication and socio-demographic data were obtained
by clinical interviews supported by medical chart infor-
mation. Premorbid functioning was measured with the
Premorbid Adjustment Scale (PAS), divided into aca-
demic and social functioning [31]. Childhood premorbid
functioning was chosen due to the young age of the
sample. Symptomatic recovery was defined as a lack of
affective and psychotic symptoms the previous 6 months
(PANSS-P less than 4 and no mood episodes as verified
by the SCID).
All clinical personnel completed a training program in
diagnostics (SCID) and symptom rating (PANSS), based
on the training program at the University of California,
Los Angeles. They also attended bi-weekly diagnostic
consensus meetings led by experienced clinicians in the
field of severe mental illness diagnostics. The inter-rater
reliability was good with an overall kappa-score of 0.77
(95% LI [0.60, 0.94]) for diagnoses and ICCs of 0.82 [32]
for PANSS positive symptoms and 0.86 for the GAF [1].
Statistical analyses
The statistical package for the social sciences (SPSS)
version 20.0 (SPSS Inc, Chicago, IL, USA) was used for
statistical analyses. Group comparisons for continuous
variables were evaluated with independent sample T-tests,
and group comparisons for dichotomous data were
evaluated with Chi-squared tests or Fischer’s exact tests as
appropriate. Level of significance was set to p < 0.05,
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use on key baseline measures and on outcome mea-
sures at one-year follow-up were first evaluated with a
multivariate analysis of variance (MANOVA) with con-
tinued cannabis use as the fixed factor. Outcome di-
mensions indicated to be different between continued
cannabis users and the rest of the patients through the
MANOVA, were followed up with a series of hierarch-
ical block-wise multiple linear regressions analyses
controlling for possible confounders of this associ-
ation. In addition to sex and age, variables with strong
correlations with both continued use of cannabis and
the outcome measure were selected as possible con-
founders, based on a bivariate analysis. Premorbid aca-
demic functioning (PAS) was added to the models in
order to investigate the role of premorbid traits in the
associations. Hence the baseline measures of YMRS
and GAF-F were entered in the first step, age and gen-
der in the second, premorbid functioning in the third
step and continued cannabis use in the fourth step of
the model. There were no associations between the
outcome measures and drug treatment adherence on
continued cocaine, amphetamine or alcohol use. These
factors were thus not added to the model. Information
about patient hospitalisations were not collected, and
thus not corrected for. Since global functioning (GAF-F)
is highly correlated with mood symptoms, a separate ana-
lysis was performed with YMRS at one-year follow up in
the second-to-last step. To evaluate the possibility of out-
liers mediating the main effect, a scatterplot of GAF-F by
YMRS scores was performed and examined. Finally, in
order to investigate if current cannabis use influenced the
results, follow-up analyses were done removing patients
with cannabis use at one time-point, but not the other,Table 1 Demographic and clinical characteristics of patients w
follow-up
No continued cannabis use
N = 56
N Mean
Age (years) 56 32.3
IDS total score 53* 11.2
YMRS total score 56 2.3
PANSS positive total score 56 8.8
GAF-F 56 65.3
N %
Females 36 64.3
Current use of antipsychotic or
mood stabilizing medication
42 79.2
*Missing data.
IDS = Inventory of depression Scale; YMRS = Young Mania Rating Scale; PANSS-P = P
of functioning.from the no continued cannabis use group, thus contrast-
ing the continuous cannabis users from the non-users.
Results
The mean age of the sample was 30.9 years (SD: 9.9 years),
and 37 patients (60%) were female. Lifetime cannabis use
was reported in 52% of the sample. There were more
males in the continued use group (p < .05) than in the
group without continued use. There were no significant
differences in key clinical characteristics at baseline, in-
cluding YMRS and GAF-F levels. There was a negative as-
sociation between YMRS and GAF-F, indicating that
patients with high levels of elevated mood had poorer
functioning. The groups did not differ in any other fea-
tures (Table 1), including the number in symptomatic re-
mission at follow-up (3 (50%) in the continued cannabis
use group vs 38 (68%) in the no continued cannabis use
group, p = .601). Four (67%) of the patients in the contin-
ued cannabis use group had not reached a level of func-
tional recovery compared to 19 (29%) patients in the
group without continued use; however, this difference was
not statistically significant (p = .390).
The MANOVA indicated that the continued use group
experienced significantly elevated mood, as measured by
the YMRS, and significantly lower global functioning as
measured by the GAF-F compared to the group without
continued use. The effect size for the difference in GAF-
F was high. There were however no significant differ-
ences in the levels of depression or psychotic symptoms
between the groups (Table 2). Repeating the analyses,
this time only contrasting continued cannabis users with
non-users, gave the same findings.
The bivariate analysis showed a correlation between
continued cannabis use and sex (−.287 p < .05), and aith- and without continued cannabis use at one year
Continued cannabis use
N = 6
SD N Mean SD p
10.0 6 30.5 9.7 .691
10.0 6 18.5 11.9 .198
4.0 6 7.3 5.5 .076
2.6 6 9.7 2.6 .439
16.0 6 49.0 16.1 .056
N % P
1 16.7 .035
4 66.7 .605
ositive and Negative Syndrome Scale-Psychotic; GAF-F = Global assessment
Table 2 Levels of symptoms and functioning in patients with and without continued cannabis use at one year follow-up
(MANOVA between-subject effects)
No continued cannabis use N = 56 Continued cannabis use N = 6
Measure Mean SD Mean SD Mean square F P d
GAF-F 66.02 15.31 49.00 16.11 1561.12 6.599 .013 1.4
PANSS-P 8.70 2.55 9.67 2.58 5.05 .774 .383 0.9
IDS 11.17 9.89 18.50 11.89 289.60 2.802 .100 0.1
YMRS 2.25 3.90 7.33 5.47 139.53 8.469 .005 −0.3
Wilks’ λ 3.299 p = .017
GAF-F = Global assessment of functioning; PANSS-P = Positive and Negative Syndrome Scale-Psychotic; IDS = Inventory of depression Scale; YMRS = Young Mania
Rating Scale. Significant values in boldface.
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GAF-F at baseline (−.347 p < .01), and between sex and
premorbid academic functioning (.357 p < .01). In the
regression analysis of elevated mood (Table 3), the ini-
tial level of elevated mood contributed significantly and
with an even stronger association between elevated
mood at follow-up and continued cannabis use than in-
dicated by the bivariate analysis. After controlling for
possible confounders of the relationship between global
functioning at follow-up and continued cannabis use
(Table 4), we found that baseline global functioning and
continued cannabis use both contributed significantly
in the final model (4A). When correcting for level of
elevated mood (YMRS scores) at the second to last step,
the impact of continued cannabis use was reduced to a
trend level of significance (4B). Gender, age and pre-
morbid functioning (as represented by the childhood
level of academic functioning in the presented final
model) did not contribute significantly to any of the
models. The scatterplot did not indicate any outliers
(Figure 1).Table 3 Multiple regression analysis with elevated mood (YM
Block model summary for each step
Block no. variable R2 change F change
Constant … …
1 .098 6.526
YMRS (Baseline)
2 .024 .791
Sex
Age
3 .042 2.862
Premorbid childhood
academic functioning
4 .115 8.913
Continued use of cannabis
Total model: F 4.329 p = .002. Adj r2 .214.Discussion
The main result of the current study is that continued
cannabis use had a statistically significant association
with elevated mood but not with depressive or psychotic
symptoms, over a one year follow-up period in a sample
of first treatment BD-I patients. This relationship was
not explained by differences in age, gender, premorbid
functioning or symptoms at baseline. Continued canna-
bis use also had a significant association with poorer glo-
bal functioning, but this association seemed to be
mediated by the elevated mood levels.
The finding of an association between continued canna-
bis use and elevated mood confirms findings from the two
existing first-hospitalization samples in addition to several
multi-episode samples [2,6,14,19,20,22,33,34] and sup-
ports the hypothesis that cannabis use in these groups is
particularly associated with a higher risk for elevated
mood [3-6]. The association was not fully explained by
baseline levels of mood symptoms. Furthermore, premor-
bid functioning did not contribute to the explanation,
contrary to findings in schizophrenia [35,36].RS scores) at 1 year as dependent variable
Contribution of separate variables for last step
Beta t P Value 95% CI of B
Lower Upper
2.630 .011 .423 3.111
.313 2.555 .013 .047 .389
-.076 -.604 .548 −2.886 1.547
-.152 −1.201 .235 -.179 .045
.212 −1.629 .096 -.140 1.664
.360 2.985 .004 1.729 8.781
Table 4 Multiple regression analysis with GAF-F at one year follow-up as dependent variable
Block model summary for each step Contribution of separate variables for last step
Block no. variable R2 change F change Beta t P Value 95% CI of B
Lower Upper
Constant … … 4.432 .000 22.543 59.633
1 .095 6.270
GAF-F (Baseline) .308 2.504 .015 .087 .779
2 .024 .780
Sex -.158 −1.247 .217 −13.794 3.202
Age -.020 -.162 .872 -.461 .392
3 .028 1.895
Premorbid childhood academic functioning -.178 −1.377 .174 5.997 1.110
Model A
4 .119 9.052
Continued use of cannabis -.363 −3.009 .004 −33.745 −6.770
Model B
4 .277 26.934
YMRS (at 1 yr) -.565 -.5190 .000 −2.991 −1.325
5 .032 3.224
Continued use of cannabis -.200 −1.796 .078 −23.582 1.293
Total model: A F 4.047 p = .003. Adj r2 .200.
Total model: B F 7.675 p = .000. Adj r2 .456.
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ued cannabis group is in line with previous studies of
multi-episode inpatients with BD [20,33] and negative
effects of continued cannabis use in general in BD
[37,38]. Our findings indicate that the reduction in glo-
bal function is partly mediated by elevated mood. The
lack of an association between continued cannabis use
and depression is in line with a recent systematic reviewFigure 1 GAF-F by YMRS with or without continued cannabis use.and meta-analysis of mainly multi-episode samples [39].
The lack of an association with psychotic features is
slightly surprising given the extensive amount of studies
on the relationship between cannabis and psychosis risk
[40-43], but we cannot rule out a type II error due the
low number of continued cannabis users, and this find-
ing warrants further research. The YMRS contains items
of psychotic manic symptoms [29]. The lack of an asso-
ciation between continued cannabis use and psychotic
features could strengthen the notion of a primary associ-
ation to mood symptoms since this indicates that the
higher YMRS scores are not mainly based on psychosis-
related items [29], a view supported by the findings of
an association between poorer global functioning and el-
evated mood also at baseline. The effect of continued
cannabis use on outcome measures after 12 months did
not seem to be explained by premorbid traits, further
strengthening a hypothesis of a direct association be-
tween cannabis use and outcome.
Strengths and limitations
The main strength of the study is the well characterized
and relatively large prospective sample of patients
followed during one year after the first treatment for
mania in BD-I. The catchment area based consecutive
sampling procedure including both in-and outpatient
treatments services gives the sample a high degree of
representativity.
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limitation, but is unlikely to induce type I errors since
results did not appear to be driven by outliers. However,
type II errors cannot be ruled out. This is a longitudinal
study with two cross-sectional points of assessment; we
thus lack reliable data of temporal sequencing of canna-
bis use and mood symptoms in the follow up period. It
is thus not possible to conclude with certainty which
phenomenon that drives the other. Information about
cannabis use was based on self-reports. Self-reports of
substance use have however been shown to have consid-
erable validity in earlier studies [44-46].
Conclusion
In conclusion, the current study showed that patients
with continued cannabis use throughout the first year of
treatment of BD I were at higher risk for elevated mood
and worse global functioning compared to the patients
without continued cannabis use. The poorer functioning
seemed to be, at least in part, mediated by the elevated
mood. These findings indicate that continued cannabis
use, also below the threshold for a DSM-IV diagnosis of
abuse or dependency, may have important clinical impli-
cations for patients suffering from BD-I. Future research
should aim at replicate these findings in a larger sample
to minimize the risk of type II errors.
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